ROVI Stock Analysis: Laboratorios Farmaceuticos | MC
Drug Manufacturers - Specialty & Generic | MC, Spain | Market Cap: 2.775m EUR | 12M Return: 0.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.82M
EPS Trend: -78.5%
Rev. Trend: -91.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Laboratorios Farmaceuticos Rovi, S.A. is a Spanish pharmaceutical company founded in 1946 and headquartered in Pozuelo de Alarcón, Spain. Listed on the Madrid Stock Exchange under the ticker ROVI, the company operates as a subsidiary of Norbel Inversiones, S.L. Its operations span Spain, the European Union, OECD countries, and other international markets.
ROVI operates across three main business areas: a portfolio of proprietary prescription products (including Enoxaparin Rovi, a low-molecular-weight heparin), hospital and diagnostic imaging products (such as Iomeron, Iopamiro, and Sonovue contrast agents), and a contract development and manufacturing (CDMO) business focused on injectables in prefilled syringes, vials, and cartridges. The CDMO segment offers services including sterile filling, terminal sterilisation, serialisation, and aggregation, serving third-party pharmaceutical clients. Its products address therapeutic areas including cardiology, womens health, anesthesia/pain, diagnostic imaging, central nervous system, urology, endocrinology, respiratory, and primary care.
The Spanish pharmaceutical industry is one of the largest in Europe, with the country hosting a significant number of GMP-certified manufacturing facilities serving both domestic and export markets. Injectable contract manufacturing in particular is a capital-intensive segment, requiring specialised aseptic processing capabilities and regulatory compliance across multiple jurisdictions.
- Moderna vaccine contract cancellation pressures contract manufacturing revenue
- Enoxaparin biosimilar competition erodes prescription product margins
- Risperidone QUAR and Okedi launches expand specialty injectable portfolio
| Net Income: 131.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 2.56 > 1.0 |
| NWC/Revenue: 52.86% < 20% (prev 44.51%; Δ 8.35% < -1%) |
| CFO/TA 0.19 > 3% & CFO 180.6m > Net Income 131.8m |
| Net Debt (32.7m) to EBITDA (200.0m): 0.16 < 3 |
| Current Ratio: 3.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.1m) vs 12m ago 0.01% < -2% |
| Gross Margin: 63.23% > 18% (prev 61.56%; Δ 1.67% > 0.5%) |
| Asset Turnover: 85.17% > 50% (prev 94.29%; Δ -9.12% > 0%) |
| Interest Coverage Ratio: 56.27 > 6 (EBIT TTM 168.7m / Interest Expense TTM 3.00m) |
| A: 0.42 (Total Current Assets 539.3m - Total Current Liabilities 147.5m) / Total Assets 926.3m |
| B: 0.64 (Retained Earnings 589.3m / Total Assets 926.3m) |
| C: 0.19 (EBIT TTM 168.7m / Avg Total Assets 870.1m) |
| D: 2.81 (Book Value of Equity 673.9m / Total Liabilities 239.6m) |
| Altman-Z'' = 9.10 = AAA |
| DSRI: 1.46 (Receivables 164.3m/116.2m, Revenue 741.1m/767.5m) |
| GMI: 0.97 (GM 61.56% / 63.23%) |
| AQI: 0.88 (AQ_t 0.06 / AQ_t-1 0.07) |
| SGI: 0.97 (Revenue 741.1m / 767.5m) |
| TATA: -0.05 (NI 131.8m - CFO 180.6m) / TA 926.3m) |
| Beneish M = -2.77 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at EUR 54.35 with a total of 170,254 shares traded. Over the past week, the price has changed by -3.48%, over one month by -5.71%, over three months by -34.27% and over the past year by +0.94%.
Current recommended Stop Loss: 53.00 (which is 2.5% or 1.3 ATR below the current price).
Laboratorios Farmaceuticos has no consensus analysts rating.
P/E Trailing = 21.0271
P/E Forward = 36.63
P/S = 3.7438
P/B = 4.2499
P/EG = 1.2569
Revenue TTM = 741.1m EUR
EBIT TTM = 168.7m EUR
EBITDA TTM = 200.0m EUR
Long Term Debt = 83.9m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 27.8m EUR (from shortTermDebt, last quarter)
Debt = 130.1m EUR (from shortLongTermDebtTotal, last quarter) + Leases 15.7m
Net Debt = 32.7m EUR (calculated: Debt 130.1m - CCE 97.4m)
Enterprise Value = 2.81b EUR (2.77b + Debt 130.1m - CCE 97.4m)
Interest Coverage Ratio = 56.27 (Ebit TTM 168.7m / Interest Expense TTM 3.00m)
EV/FCF = 24.45x (Enterprise Value 2.81b / FCF TTM 114.8m)
FCF Yield = 4.09% (FCF TTM 114.8m / Enterprise Value 2.81b)
FCF Margin = 15.49% (FCF TTM 114.8m / Revenue TTM 741.1m)
Net Margin = 17.79% (Net Income TTM 131.8m / Revenue TTM 741.1m)
Gross Margin = 63.23% ((Revenue TTM 741.1m - Cost of Revenue TTM 272.5m) / Revenue TTM)
Gross Margin QoQ = 55.56% (prev 59.87%)
Tobins Q-Ratio = 3.03 (Enterprise Value 2.81b / Total Assets 926.3m)
Interest Expense / Debt = 2.30% (Interest Expense 3.00m / Debt 130.1m)
Taxrate = 23.72% (41.0m / 172.7m)
NOPAT = 128.7m (EBIT 168.7m * (1 - 23.72%))
Current Ratio = 3.66 (Total Current Assets 539.3m / Total Current Liabilities 147.5m)
Debt / Equity = 0.19 (Debt 130.1m / totalStockholderEquity, last quarter 673.9m)
Debt / EBITDA = 0.16 (Net Debt 32.7m / EBITDA 200.0m)
Debt / FCF = 0.29 (Net Debt 32.7m / FCF TTM 114.8m)
Total Stockholder Equity = 630.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.15% (Net Income 131.8m / Total Assets 926.3m)
RoE = 20.89% (Net Income TTM 131.8m / Total Stockholder Equity 630.9m)
RoCE = 23.61% (EBIT 168.7m / Capital Employed (Equity 630.9m + L.T.Debt 83.9m))
RoIC = 16.73% (NOPAT 128.7m / Invested Capital 769.5m)
WACC = 6.86% (E(2.77b)/V(2.90b) * Re(7.10%) + D(130.1m)/V(2.90b) * Rd(2.30%) * (1-Tc(0.24)))
Discount Rate = 7.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -49.80 | Cagr: -0.58%
[DCF] Terminal Value 77.97% ; FCFF base≈100.9m ; Y1≈115.7m ; Y5≈170.3m
[DCF] Fair Price = 49.46 (EV 2.56b - Net Debt 32.7m = Equity 2.53b / Shares 51.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -78.53 | EPS CAGR: -11.24% | SUE: N/A | # QB: 0
Revenue Correlation: -91.04 | Revenue CAGR: -4.63% | SUE: 0.06 | # QB: 0
EPS current Year (2026-12-31): EPS=2.56 | Chg30d=+0.00% | Revisions=-67% | GrowthEPS=-7.0% | GrowthRev=+4.1%
EPS next Year (2027-12-31): EPS=3.47 | Chg30d=-3.04% | Revisions=-70% | GrowthEPS=+35.7% | GrowthRev=+16.0%
[Analyst] Revisions Ratio: -81% (up=0, down=13)